FindTrial
Sign In

Phase II trial of amivantamab plus monochemotherapy in platinum unfit NSCLC patients with EGFR exon20 insertion mutations

Status
Not yet recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-520676-26-00
Enrollment
35
Registered
2025-09-11
Start date
Unknown
Completion date
Unknown
Last updated
2025-10-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer (NSCLC)

Brief summary

Objective Response Rate (ORR) according to RECIST 1.1

Detailed description

Median PFS, Median OS, Duration of response, Safety

Interventions

DRUGJNJ-61186372
DRUGPemetrexed Ever Pharma 25 mg/ml concentrato per soluzione per infusione

Sponsors

Fondazione Ricerca Traslazionale
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Objective Response Rate (ORR) according to RECIST 1.1—

Secondary

MeasureTime frame
Median PFS, Median OS, Duration of response, Safety—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026